Oncology – Page 7

Harnessing Immune-Checkpoint Inhibitors in Biliary Tract Cancer: Current Benefits and Future Perspectives

By MedXY 10/29/2025

Immune-checkpoint inhibitors combined with chemotherapy have redefined treatment for advanced biliary tract cancer, offering improved survival despite challenges posed by tumor heterogeneity and biomarker limitations. Ongoing research explores novel combinations and earlier stage interventions to optimize patient outcomes.

Gastroenterology news Oncology

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A 3-Year Survival Update from the Phase III TOPAZ-1 Study

By MedXY 10/29/2025

The TOPAZ-1 study shows durvalumab combined with gemcitabine and cisplatin improves 3-year overall survival in advanced biliary tract cancer with manageable safety, establishing a new standard of care.

Gastroenterology news Oncology

Evaluating Surrogate Endpoints in Advanced Biliary Tract Cancer: Progression-Free Survival Outperforms Response Rates as a Predictor of Overall Survival

By MedXY 10/28/2025

This comprehensive analysis reveals that progression-free survival moderately correlates with overall survival in advanced biliary tract cancer, while objective response and disease control rates show poor correlation, underscoring the need for better surrogate markers in clinical trials.

Gastroenterology news Oncology

Targeting Xanthine Oxidoreductase: A New Frontier to Overcome EGFR TKI Resistance in Intrahepatic Cholangiocarcinoma

By MedXY 10/28/2025

Xanthine oxidoreductase (XOR) drives resistance to EGFR tyrosine kinase inhibitors in intrahepatic cholangiocarcinoma by stabilizing EGFR and enhancing DNA repair. Targeting XOR sensitizes tumors to EGFR TKIs and suppresses cancer progression.

Gastroenterology news Oncology

Proteogenomic Insights into Personalized Adjuvant Chemotherapy for Extrahepatic Cholangiocarcinoma

By MedXY 10/28/2025

Comprehensive proteogenomic profiling in resected extrahepatic cholangiocarcinoma reveals predictive biomarkers for tailoring adjuvant chemotherapy, offering a precision medicine approach to improve patient outcomes.

Gastroenterology news Oncology

Innovative TCR T-Cell Therapy Shows Promise in Advanced Hepatocellular and Gastric Hepatoid Carcinoma

By MedXY 10/28/2025

A phase I trial reveals that ADP-A2AFP TCR T-cell therapy, targeting AFP-expressing advanced hepatocellular carcinoma and gastric hepatoid carcinoma, is safe and exhibits early antitumor activity in patients refractory to conventional treatments.

Gastroenterology news Oncology

Unveiling the Molecular Link Between Alcohol and HBV-Driven Liver Cancer: The Role of ATF4/LPLA2-Mediated BMP Metabolism

By MedXY 10/28/2025

Chronic alcohol intake exacerbates HBV-induced hepatocellular carcinoma by activating the ATF4/LPLA2 pathway, promoting BMP metabolism and MAPK/ERK signaling, identifying LPLA2 as a potential therapeutic target and prognostic marker.

news Oncology

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma: Long-Term Outcomes and Immunological Biomarkers

By MedXY 10/28/2025

Neoadjuvant nivolumab combined with ipilimumab shows promising long-term survival and safety in potentially resectable hepatocellular carcinoma, with immunotherapy-induced tertiary lymphoid structures correlating with response.

news Oncology

Navigating Non-Proportional Hazards in Hepatocellular Carcinoma Trials: Enhancing Interim Analysis Accuracy

By MedXY 10/28/2025

Non-proportional hazards in hepatocellular carcinoma immunotherapy trials can distort interim and final survival outcomes. Employing tailored statistical strategies ensures robust, clinically meaningful analyses and informed decision-making.

news Oncology

Lenvatinib as a Promising Second-Line Therapy for Advanced Hepatocellular Carcinoma Post-Atezolizumab Plus Bevacizumab Failure: Insights from a Multicenter Phase II Trial

By MedXY 10/28/2025

A recent phase II trial demonstrates lenvatinib's efficacy and manageable safety as a second-line treatment for unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab.

news Oncology

Alcohol’s Amplifying Effect on HBV-Related Liver Cancer: New Insights into Metabolic Reprogramming

By MedXY 10/27/2025

This article explores how alcohol consumption worsens HBV-induced hepatocellular carcinoma by promoting ER stress and lipid metabolic disturbances, highlighting potential therapeutic targets like LPLA2 and BMP.

news Oncology Urology

Rethinking Gleason Grade Group 1 Prostate Cancer: Insights from a Large-Scale Cohort Study

By MedXY 10/27/2025

This study highlights the heterogeneity of GG1 prostate cancer and its implications for classification and management strategies.

Gastroenterology news Oncology

Microbial Metabolism Dysfunction and Its Impact on Liver Injury After TACE in Hepatocellular Carcinoma

By MedXY 10/27/2025

This review explores how gut microbiota disturbances, especially L. reuteri and its metabolite ILA, influence post-TACE liver injury and prognosis in HCC patients, highlighting potential microbiota-targeted therapies.

Internal Medicine news Oncology Transplantation

Balancing Efficacy and Safety: Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients with Advanced Cancers

By MedXY 10/27/2025

This systematic review and meta-analysis evaluate cancer and graft outcomes in transplant recipients treated with immune checkpoint inhibitors, revealing differences by cancer type and potential strategies to reduce rejection risk.

news Oncology

Revolutionizing Early-Stage Cervical Cancer Management: Insights from the SENTIX Sentinel Lymph Node Trial

By MedXY 10/25/2025

The SENTIX trial shows that sentinel lymph node biopsy without full pelvic lymphadenectomy is safe in early-stage cervical cancer, potentially reducing surgical morbidity without compromising oncologic outcomes.

news Oncology

Reevaluating Lymph Node Management in Early-Stage Cervical Cancer: Sentinel Biopsy Alone Shows Promise

By MedXY 10/25/2025

A large randomized trial finds sentinel lymph-node biopsy alone is noninferior to lymphadenectomy in early cervical cancer, with fewer complications and comparable survival outcomes.

news Oncology Respiratory

Emerging Promise of Sevabertinib for HER2-Mutant Non-Small-Cell Lung Cancer: A New Hope

By MedXY 10/25/2025

This article reviews recent clinical trial data showing sevabertinib's efficacy and safety in treating HER2-mutant NSCLC, highlighting its potential to fill an unmet therapeutic gap.

news Oncology Respiratory

Efficacy of Afatinib Combined with Chemotherapy in Post-Osimertinib EGFR-Mutated NSCLC: Insights from the NEJ025B Study

By MedXY 10/25/2025

This phase II study evaluates the effectiveness and safety of afatinib with platinum-based chemotherapy in NSCLC patients resistant to first-line osimertinib, highlighting promising outcomes and manageable toxicity.

news Oncology Respiratory

Advancing Treatment in EGFR-Mutant NSCLC: Efficacy of Amivantamab Plus Lazertinib Post-Resistances

By MedXY 10/25/2025

This article reviews the CHRYSALIS-2 cohort A study demonstrating the potential of combined amivantamab and lazertinib therapy in heavily pretreated EGFR-mutant NSCLC patients.

Oncology Respiratory

Enhanced Survival in EGFR-Mutated NSCLC: Impact of Amivantamab-Lazertinib vs. Osimertinib

By MedXY 10/25/2025

This article reviews a phase 3 trial comparing overall survival of amivantamab-lazertinib versus osimertinib in untreated EGFR-mutated advanced NSCLC, highlighting efficacy, safety, and clinical implications.